This strategic collaboration, formally announced in early 2024, unites two powerhouses in healthcare: Labcorp, a global leader in clinical laboratory…
Read More
Labcorp and Children’s Hospital of Philadelphia Forge Alliance to Revolutionize Pediatric Diagnostics and Expand National Access
The landscape of clinical diagnostics is poised for a significant transformation following the announcement of a strategic collaboration between Labcorp,…
Read More
Labcorp and Children’s Hospital of Philadelphia Forge Strategic Alliance to Revolutionize Pediatric Diagnostics and National Access
Labcorp, a leading global life sciences company, and the Children’s Hospital of Philadelphia (CHOP), a globally recognized leader in pediatric…
Read More
Labcorp and CHOP Launch Pediatric Diagnostics Partnership to Expand Advanced Testing and Drive Clinical Lab Growth
The diagnostic landscape for pediatric patients is poised for significant transformation following the announcement of a strategic collaboration between Labcorp,…
Read More
Labcorp and Children’s Hospital of Philadelphia Forge Strategic Alliance to Advance Pediatric Diagnostics and National Access
Labcorp, a leading global life sciences company, and the Children’s Hospital of Philadelphia (CHOP), a preeminent pediatric research and clinical…
Read More
Labcorp and CHOP Launch Pediatric Diagnostics Partnership to Expand Advanced Testing and Drive Clinical Lab Growth
This strategic collaboration, officially announced by the two institutions, marks a significant development in the landscape of pediatric healthcare, aiming…
Read More
Filspari Secures Landmark FDA Approval for Focal Segmental Glomerulosclerosis (FSGS) in Adults and Pediatric Patients Aged Eight and Above
Travere Therapeutics has achieved a significant milestone in the treatment of rare kidney diseases with the U.S. Food and Drug…
Read More
FDA Proposes Permanent Authorization of Rare Pediatric Disease Priority Review Voucher Program to Foster Regulatory Stability
The United States Food and Drug Administration (FDA) is making a significant move to permanently authorize the rare pediatric disease…
Read More
Opdivo Secures Landmark US and EU Approvals for Classical Hodgkin Lymphoma Across Pediatric and Adult Populations
Bristol Myers Squibb’s (BMS) groundbreaking immunotherapy, Opdivo (nivolumab), has achieved a significant milestone with dual approvals from the U.S. Food…
Read MoreYOU MAY HAVE MISSED
